BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36388671)

  • 1. Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report.
    Wang Y; Li J; Xu Q; Li K; Zhang C; Chen P
    J Gastrointest Oncol; 2022 Oct; 13(5):2667-2671. PubMed ID: 36388671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
    Wan Y; Luo D
    J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
    He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
    J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
    Tan S; Zhang S; Zhou N; Cai X; Yi C; Gou H
    Cancer Med; 2023 Dec; 12(24):22038-22046. PubMed ID: 38063405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report.
    Qu FJ; Wu S; Kong Y
    World J Gastrointest Oncol; 2023 May; 15(5):902-910. PubMed ID: 37275454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary experience of oral fruquintinib-capecitabine as a new maintenance treatment strategy for advanced colorectal cancer in the era of coronavirus disease 2019 (COVID-19): case report and literature review.
    Quan M; Chen Z; Chen J; Hai Y; Gao Y
    J Gastrointest Oncol; 2022 Oct; 13(5):2660-2666. PubMed ID: 36388683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer.
    Song Y; Qu T; Zhang H; Sun Y; Cui C; Chi Y; Zhang W; Wang X; Yang L
    Cancer Manag Res; 2021; 13():6199-6205. PubMed ID: 34393513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report.
    Kong LZ; Zheng Y; Li K
    Immunotherapy; 2024 Feb; 16(2):107-114. PubMed ID: 38112011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports.
    Wu D; Wang Q; Yan S; Sun X; Qin Y; Yuan M; Wang NY; Huang XT
    World J Clin Cases; 2024 Mar; 12(7):1296-1304. PubMed ID: 38524525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
    Li J; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Xu R; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Shen L; Chen H; Wang S; Wang H; Fan S; Guo X; Wang N; Han R; Zhang B; Qin S
    Adv Ther; 2020 Nov; 37(11):4585-4598. PubMed ID: 32901330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
    Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
    Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
    Front Oncol; 2020; 10():587692. PubMed ID: 33282739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fruquintinib beneficial in elderly patient with neoplastic pericardial effusion from rectal cancer: A case report.
    Zhang Y; Zou JY; Xu YY; He JN
    World J Clin Cases; 2021 Jul; 9(21):6170-6177. PubMed ID: 34368339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer.
    Shu Y; Zheng S
    Front Oncol; 2021; 11():688231. PubMed ID: 34290985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
    Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
    Front Oncol; 2022; 12():851756. PubMed ID: 35875064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of an elderly patient with high-grade colorectal cancer in poor general condition who showed near complete response to chemotherapy and achieved long-term survival.
    Kanemoto Y; Tsurita G; Kurokawa T; Azuma Y; Yazawa K; Murakami Y
    Int J Surg Case Rep; 2019; 58():186-189. PubMed ID: 31060020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
    Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
    Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
    Liu S; Lu L; Pan F; Yang C; Liang J; Liu J; Wang J; Shen R; Xin FZ; Zhang N
    Oncol Res; 2022 May; 29(1):25-31. PubMed ID: 35063062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.